ANKRD28 and Miyoshi myopathy: Ankyrin repeat domain 28 (ANKRD28) has been confirmed as an oncogene in acute myeloid leukemia (AML).[11, 12] Analogously, super‐enhancers‐regulated ANKRD28 correlates with poor prognosis in patients with germinal center B‐cell diffuse large B‐cell lymphoma (GCB‐DLBCL).[13] Despite the evidence in other hematologic neoplasms, the role of ANKRD28, especially its non‐coding DNA regions that served as enhancers, remains unclear in MM.